US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8719963D0
(en)
|
1987-08-24 |
1987-09-30 |
Cattaneo A |
Recombinant dna products
|
US5831034A
(en)
|
1987-11-13 |
1998-11-03 |
Hermann Katinger |
Human monoclonal anti-HIV-I-antibodies
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
DE69333950T2
(de)
|
1992-05-18 |
2006-08-17 |
Genentech, Inc., South San Francisco |
Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
AU697387C
(en)
|
1994-09-16 |
2006-03-02 |
Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 |
Polypeptides with Fc binding ability
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
IL111196A0
(en)
|
1994-10-07 |
1994-12-29 |
Yeda Res & Dev |
Peptides and pharmaceutical compositions comprising them
|
US6808709B1
(en)
*
|
1994-12-30 |
2004-10-26 |
The Regents Of The University Of California |
Immunoglobulins containing protection proteins and their use
|
US6165463A
(en)
*
|
1997-10-16 |
2000-12-26 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
ATE219105T1
(de)
|
1995-04-19 |
2002-06-15 |
Polymun Scient Immunbio Forsch |
Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
|
US20050003431A1
(en)
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
US7311912B1
(en)
*
|
1997-01-10 |
2007-12-25 |
Plantbodies Corporation |
Epithelial tissue targeting agent
|
US6045774A
(en)
*
|
1997-01-10 |
2000-04-04 |
Epicyte Pharmaceutical Inc. |
J chain polypeptide targeting molecule linked to an imaging agent
|
US20040009166A1
(en)
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US6284536B1
(en)
|
1998-04-20 |
2001-09-04 |
The Regents Of The University Of California |
Modified immunoglobin molecules and methods for use thereof
|
ATE437227T1
(de)
|
1999-01-07 |
2009-08-15 |
Zymogenetics Inc |
Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
|
JP2002544123A
(ja)
|
1999-04-14 |
2002-12-24 |
スミスクライン・ビーチャム・コーポレイション |
エリトロポイエチン受容体抗体
|
CA2375912C
(en)
|
1999-06-09 |
2014-03-11 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
WO2001012820A1
(en)
|
1999-08-17 |
2001-02-22 |
Health Research Institute |
Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
|
EP1212422B1
(en)
*
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US20050287153A1
(en)
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US20020168367A1
(en)
|
2000-04-28 |
2002-11-14 |
Planet Biotechnology Incorporated |
Novel immunoadhesins for treating and preventing viral and bacterial diseases
|
JP5008811B2
(ja)
|
2000-04-28 |
2012-08-22 |
プラネット・バイオテクノロジー・インコーポレイテッド |
ライノウイルス感染を防止するための免疫接着物
|
EP2394659B1
(en)
*
|
2000-05-10 |
2014-01-22 |
Signe BioPharma Inc. |
Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
|
JP2004502450A
(ja)
|
2000-07-10 |
2004-01-29 |
ノバルティス アクチエンゲゼルシャフト |
ターゲッティング遺伝子送達のための二官能性分子およびそれと複合化されたベクター
|
AU8886601A
(en)
|
2000-09-07 |
2002-03-22 |
John R Schreiber |
Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
|
US7138496B2
(en)
|
2002-02-08 |
2006-11-21 |
Genetastix Corporation |
Human monoclonal antibodies against human CXCR4
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
US7402312B2
(en)
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
NZ513418A
(en)
|
2001-08-07 |
2004-04-30 |
Univ Massey |
Vaccine comprising proteins from mycobacterium paratuberculosis
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
WO2003068821A2
(en)
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
PT3483183T
(pt)
|
2002-03-01 |
2021-06-02 |
Immunomedics Inc |
Imunoconjugado compreendendo anticorpos rs7 humanizados
|
ES2350477T5
(es)
|
2002-03-01 |
2020-05-06 |
Immunomedics Inc |
Internalización de anticuerpos anti-CD74 y métodos de uso
|
MXPA04010013A
(es)
*
|
2002-04-12 |
2004-12-13 |
Medarex Inc |
Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.
|
CN1675245B
(zh)
|
2002-06-14 |
2011-01-12 |
免疫医疗公司 |
人源化单克隆抗体hPAM4
|
US7601351B1
(en)
|
2002-06-26 |
2009-10-13 |
Human Genome Sciences, Inc. |
Antibodies against protective antigen
|
ES2442615T5
(es)
|
2002-07-18 |
2023-03-16 |
Merus Nv |
Producción recombinante de mezclas de anticuerpos
|
US7300655B2
(en)
|
2002-08-01 |
2007-11-27 |
Immunomedics, Inc. |
Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
|
AU2003275029A1
(en)
|
2002-09-27 |
2004-04-19 |
Brigham And Women's Hospital, Inc. |
Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
EP1626992B1
(en)
|
2003-05-23 |
2010-06-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
WO2005005636A1
(ja)
|
2003-07-15 |
2005-01-20 |
Chugai Seiyaku Kabushiki Kaisha |
形質転換細胞によるIgMの産生とその定量方法
|
US7109304B2
(en)
|
2003-07-31 |
2006-09-19 |
Immunomedics, Inc. |
Humanized anti-CD19 antibodies
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
EP1686137A4
(en)
|
2003-10-09 |
2009-10-28 |
Chugai Pharmaceutical Co Ltd |
PROCESS FOR STABILIZING PROTEIN SOLUTIONS
|
WO2005040220A1
(en)
*
|
2003-10-16 |
2005-05-06 |
Micromet Ag |
Multispecific deimmunized cd3-binders
|
FR2861255B1
(fr)
|
2003-10-24 |
2006-02-17 |
Centre Nat Rech Scient |
Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
|
US20090041659A1
(en)
|
2003-12-05 |
2009-02-12 |
Schreiber John R |
Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
BRPI0517057A
(pt)
|
2004-11-05 |
2008-09-30 |
Palingen Inc |
composição para induzir ferimento de membrana celular; composição para aumentar o ferimento da membrana celular em uma célula linfóide; composição para permeabilizar uma célula; composição para induzir ferimento da membrana celular em células b; composição para aumentar o ferimento da membrana celular induzido por um anticorpo de ferimento de membrana celular; método de tratamento de um mamìfero que sofre de uma condição distinta por uma hiperproliferação de células; método para matar uma célula cancerosa; método para induzir ferimento de membrana celular em uma célula linfóide em um paciente humano; método para induzir ferimento da membrana celular; método para permeabilizar uma célula; método de purgar a medula óssea de células b malignas de um paciente com esta necessidade; estojo para determinar o limite da dose para um agente polivalente que induz o ferimento da membrana celular em um mamìfero; estojo para determinar o limite da dose para um anticorpo de ferimento de membrana celular em um mamìfero; uso de um agente polivalente de ferimento de membrana celular; e uso de um anticorpo de ferimento de membrana celular
|
US7251164B2
(en)
|
2004-11-10 |
2007-07-31 |
Innovative Silicon S.A. |
Circuitry for and method of improving statistical distribution of integrated circuits
|
US20090311280A1
(en)
|
2004-12-09 |
2009-12-17 |
La Jolla Institute For Allergy And Immunology |
Novel tnf receptor regulatory domain
|
ES2665422T3
(es)
|
2005-03-03 |
2018-04-25 |
Immunomedics Inc. |
Anticuerpos L243 humanizados
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US20110129412A1
(en)
|
2005-06-02 |
2011-06-02 |
Astrazeneca Ab |
Antibodies Directed to CD20 and Uses Thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
AU2006327175A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Medimmune, Llc |
Epha2 bite molecules and uses thereof
|
AU2007249488B2
(en)
|
2006-05-15 |
2011-11-10 |
Immunonomedics, Inc. |
Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
|
WO2007134384A2
(en)
|
2006-05-19 |
2007-11-29 |
Children Youth And Women's Health Service |
Selective modulation of receptor signalling
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
WO2008127271A2
(en)
|
2006-09-08 |
2008-10-23 |
Abbott Laboratories |
Interleukin -13 binding proteins
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
AU2007353396C1
(en)
|
2006-11-02 |
2013-06-27 |
Biomolecular Holdings Llc |
Hybrid immunoglobulins with moving parts
|
US20080145420A1
(en)
|
2006-12-13 |
2008-06-19 |
Simon Michael R |
HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
|
US20100184959A1
(en)
|
2007-03-19 |
2010-07-22 |
Medimmune Limited |
Polypeptide Variants
|
US20100298223A1
(en)
|
2007-05-02 |
2010-11-25 |
Dietmar Rudolf Fries |
Fibrinogen for treatment of bleeding in trauma and platelet disorders
|
WO2009013620A2
(en)
|
2007-06-11 |
2009-01-29 |
Erasmus University Medical Center Rotterdam |
Homologous recombination
|
CA2698419C
(en)
|
2007-09-07 |
2019-11-12 |
Edward Dolk |
Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
WO2009062151A1
(en)
|
2007-11-08 |
2009-05-14 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
WO2009106073A2
(en)
|
2008-02-28 |
2009-09-03 |
Dako Denmark A/S |
Mhc multimers in borrelia diagnostics and disease
|
ITTO20080313A1
(it)
|
2008-04-22 |
2009-10-23 |
Marco Colombatti |
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
|
KR20110028543A
(ko)
|
2008-07-11 |
2011-03-18 |
씨 레인 바이오테크놀로지스, 엘엘씨 |
항체 대용물 카파 경쇄 서열을 포함하는 구축물 및 라이브러리
|
US10369204B2
(en)
|
2008-10-02 |
2019-08-06 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
AU2009313551B2
(en)
|
2008-11-07 |
2015-12-17 |
Fabrus Llc |
Anti-DLL4 antibodies and uses thereof
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
PL2519543T3
(pl)
|
2009-12-29 |
2016-12-30 |
|
Białka wiążące heterodimery i ich zastosowania
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
MX2012009321A
(es)
*
|
2010-02-11 |
2012-11-21 |
Alexion Pharma Inc |
Metodos terapeuticos que utilizan anticuerpos anti-cd200.
|
EP3345619A1
(en)
|
2010-10-19 |
2018-07-11 |
Mayo Foundation for Medical Education and Research |
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
|
WO2012088290A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
CA2853114A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Bispecific immunobinders directed against tnf and il-17
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2791171A1
(en)
|
2011-12-16 |
2014-10-22 |
Synthon Biopharmaceuticals B.V. |
EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
|
MX363819B
(es)
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
KR20150003195A
(ko)
|
2012-04-05 |
2015-01-08 |
고트프리드 히믈러 |
분비 면역글로불린 복합체
|
US20150175678A1
(en)
|
2012-06-15 |
2015-06-25 |
Beth Israel Deaconess Medical Center, Inc. |
IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
|
EP2880057A4
(en)
|
2012-08-02 |
2016-03-23 |
Jn Biosciences Llc |
MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
US10066238B2
(en)
*
|
2013-02-11 |
2018-09-04 |
University Of Louisville Research Foundation, Inc. |
Methods for producing antibodies
|
US9487773B2
(en)
|
2013-03-01 |
2016-11-08 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Cell-based methods for coupling protein interactions and binding molecule selection
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
BR112016001420A2
(pt)
|
2013-08-02 |
2018-01-23 |
Aduro Biotech Holdings Europe B V |
combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
|
US20150038682A1
(en)
|
2013-08-02 |
2015-02-05 |
Jn Biosciences Llc |
Antibodies or fusion proteins multimerized via homomultimerizing peptide
|
AU2014332458B2
(en)
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
CA2931641C
(en)
|
2013-12-30 |
2022-05-10 |
Epimab Biotherapeutics Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
NZ722120A
(en)
|
2014-01-16 |
2022-07-29 |
Mario Umberto Francesco Mondelli |
Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
|
CA2939191C
(en)
|
2014-02-10 |
2023-04-04 |
Igm Biosciences, Inc. |
Iga multi-specific binding molecules
|
ES2770684T3
(es)
*
|
2014-03-14 |
2020-07-02 |
Novartis Ag |
Moléculas de anticuerpos contra LAG-3 y usos de los mismos
|
WO2015153912A1
(en)
|
2014-04-03 |
2015-10-08 |
Igm Biosciences, Inc. |
Modified j-chain
|
PT3247728T
(pt)
|
2015-01-20 |
2020-07-16 |
Igm Biosciences Inc |
Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
|
CN107532188B
(zh)
|
2015-03-04 |
2022-05-10 |
Igm生物科学股份有限公司 |
Cd20结合分子及其用途
|
CA2980751A1
(en)
|
2015-03-25 |
2016-09-29 |
Stephen F. Carroll |
Multi-valent hepatitis b virus antigen binding molecules and uses thereof
|
AU2016249404B2
(en)
|
2015-04-17 |
2021-01-21 |
Igm Biosciences, Inc. |
Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
EP3355913A1
(en)
|
2015-09-30 |
2018-08-08 |
IGM Biosciences A/S |
Binding molecules with modified j-chain
|
WO2017196867A1
(en)
|
2016-05-09 |
2017-11-16 |
Igm Biosciences, Inc. |
Anti-pd-l1 antibodies
|
CA3030647A1
(en)
|
2016-07-20 |
2018-01-25 |
Igm Biosciences, Inc. |
Multimeric ox40 binding molecules and uses thereof
|
CA3030640A1
(en)
|
2016-07-20 |
2018-01-25 |
Igm Biosciences, Inc. |
Multimeric cd40 binding molecules and uses thereof
|
US20190330360A1
(en)
|
2016-07-20 |
2019-10-31 |
Igm Biosciences, Inc. |
Multimeric gitr binding molecules and uses thereof
|
AU2017299608A1
(en)
|
2016-07-20 |
2019-02-07 |
Igm Biosciences, Inc. |
Multimeric CD137/4-1BB binding molecules and uses thereof
|
EP3607091A4
(en)
|
2017-04-07 |
2021-01-20 |
IGM Biosciences, Inc. |
MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
|
AU2019224136A1
(en)
|
2018-02-26 |
2020-09-10 |
Igm Biosciences, Inc. |
Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
|
CN111787951A
(zh)
|
2018-03-01 |
2020-10-16 |
Igm生物科学股份有限公司 |
影响IgM血清半衰期的IgM Fc和J链突变
|
WO2020086745A1
(en)
|
2018-10-23 |
2020-04-30 |
Igm Biosciences, Inc. |
MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
|
WO2020163646A1
(en)
|
2019-02-08 |
2020-08-13 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
US20230203119A1
(en)
|
2019-08-15 |
2023-06-29 |
Igm Biosciences, Inc. |
Immunostimulatory multimeric binding molecules
|
JP2022545655A
(ja)
|
2019-08-17 |
2022-10-28 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
多量体の二重特異性抗cd123結合分子及びその使用
|
EP4017533A4
(en)
|
2019-08-23 |
2024-03-27 |
Igm Biosciences Inc |
IGM GLYCOVARIANTS
|
US20220372142A1
(en)
|
2019-09-19 |
2022-11-24 |
Igm Biosciences, Inc. |
Multimeric antibodies with enhanced selectivity for cells with high target density
|
BR112022013071A2
(pt)
|
2020-01-06 |
2022-09-20 |
Igm Biosciences Inc |
Moléculas de ligação multiméricas altamente sialiladas
|
IL297029A
(en)
|
2020-04-22 |
2022-12-01 |
Igm Biosciences Inc |
Multimeric binding compounds as pd-1 agonists
|
IL297619A
(en)
|
2020-05-12 |
2022-12-01 |
Igm Biosciences Inc |
Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer
|
CA3187008A1
(en)
|
2020-07-27 |
2022-02-03 |
Paul R. Hinton |
Multimeric coronavirus binding molecules and uses thereof
|
US20240002526A1
(en)
|
2020-11-17 |
2024-01-04 |
Igm Biosciences, Inc. |
Uses of effector cell engaging molecules with moieties of differing potencies
|
US20220267415A1
(en)
|
2021-02-17 |
2022-08-25 |
The Board Of Regents Of The University Of Texas System |
Multimeric sars-cov-2 binding molecules and uses thereof
|
JP2024508709A
(ja)
|
2021-02-17 |
2024-02-28 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
抗cd123結合分子及びその使用法
|